Loading...
Market
Who will be the primary manufacturer of the PCANS nasal spray for mass production by June 30, 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Company announcements and industry reports
Story
New Drug-Free Nasal Spray Shows Nearly 100% Protection Against COVID-19, Influenza, and Bacteria
Sep 25, 2024, 06:06 PM
Researchers at Brigham and Women's Hospital, led by N Joshi and Jeff Karp, have developed an innovative drug-free nasal spray that shows promise in warding off respiratory infections. Preclinical studies indicate that the spray, known as Pathogen Capture and Neutralizing Spray (PCANS), offers nearly 100% protection against COVID-19, influenza, and pneumonia-causing bacteria. The spray works by blocking and neutralizing viruses and bacteria, potentially serving as an additional public health tool when masks and vaccines are insufficient. The development has been published in Advanced Materials and has received recognition from the Stepping Strong COVID Award.
View original story
Similar markets
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%
GSK • 33%
Sanofi • 33%
Seqirus • 33%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Less than 1 million units • 25%
1 to 2 million units • 25%
2 to 3 million units • 25%
More than 3 million units • 25%